These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 2104811)

  • 1. Pregnancy rate and ovarian hyperstimulation after luteal human chorionic gonadotropin in in vitro fertilization stimulated with gonadotropin-releasing hormone analog and menotropins.
    Herman A; Ron-El R; Golan A; Raziel A; Soffer Y; Caspi E
    Fertil Steril; 1990 Jan; 53(1):92-6. PubMed ID: 2104811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteinizing response to human chorionic gonadotropin does not predict outcome in gonadotropin releasing hormone agonist-suppressed/human menopausal gonadotropin-stimulated in vitro fertilization (IVF) cycles.
    Penzias AS; Shamma FN; Gutmann JN; Seifer DB; DeCherney AH; Lavy G
    J Assist Reprod Genet; 1992 Jun; 9(3):244-7. PubMed ID: 1525454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention.
    Forman RG; Frydman R; Egan D; Ross C; Barlow DH
    Fertil Steril; 1990 Mar; 53(3):502-9. PubMed ID: 2106456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian hyperstimulation syndrome following D-Trp-6 luteinizing hormone-releasing hormone microcapsules and menotropin for in vitro fertilization.
    Golan A; Ron-El R; Herman A; Weinraub Z; Soffer Y; Caspi E
    Fertil Steril; 1988 Dec; 50(6):912-6. PubMed ID: 2974429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of GnRH analog for induction of the ovulatory surge of gonadotropins in patients at risk of the ovarian hyperstimulation syndrome.
    Kulikowski M; Wołczyński S; Kuczyński W; Grochowski D; Szamatowicz M
    Gynecol Endocrinol; 1995 Jun; 9(2):97-102. PubMed ID: 7502696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian response and pregnancy rates in in vitro fertilization, gamete intrafallopian transfer, and in vivo fertilization therapies after combined gonadotropin-releasing hormone agonist/human menopausal gonadotropin stimulation.
    Lindner C; Braendle W; Lichtenberg V; Köhler S; Bettendorf G
    Gynecol Obstet Invest; 1990; 29(2):140-4. PubMed ID: 2139861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progesterone alone versus progesterone combined with HCG as luteal support in GnRHa/HMG induced IVF cycles: a randomized clinical trial.
    Mochtar MH; Hogerzeil HV; Mol BW
    Hum Reprod; 1996 Aug; 11(8):1602-5. PubMed ID: 8921100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in in vitro fertilization.
    Segal S; Casper RF
    Fertil Steril; 1992 Jun; 57(6):1254-8. PubMed ID: 1601147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inclusion of standard and low-dose gonadotropin releasing hormone-analog (short protocol) in controlled ovarian hyperstimulation regimens in normogonadotropic patients aged 40-48 years who are undergoing in vitro fertilization.
    Avrech OM; Orvieto R; Pinkas H; Sapir-Rufas O; Feldberg D; Fisch B
    Gynecol Endocrinol; 2004 Nov; 19(5):247-52. PubMed ID: 15726912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal profiles in successful and unsuccessful implantation in IVF-ET after combined GnRH agonist/gonadotropin treatment for superovulation and hCG luteal support.
    Balasch J; Creus M; Fábregues F; Carmona F; Casamitjana R; Peñarrubia J; Rivera F; Vanrell JA
    Gynecol Endocrinol; 1995 Mar; 9(1):51-8. PubMed ID: 7793300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum and follicular fluid (FF) estradiol (E2) levels in ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) and gamete intrafallopian transfer (GIFT) conception cycles after pituitary suppression.
    Leya J; Molo MW; Olson D; Radwanska E
    J In Vitro Fert Embryo Transf; 1991 Jun; 8(3):137-40. PubMed ID: 1919258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
    Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
    Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [GnRH agonist triggering in IVF and luteal phase support in women at risk of ovarian hyperstimulation syndrome].
    Guivarc'h-Levêque A; Jaffré F; Homer L; Moy L; Priou G; Colleu D; Denis I; Arvis P
    Gynecol Obstet Fertil; 2013 Sep; 41(9):511-4. PubMed ID: 23972925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of gonadotrophin-releasing hormone agonists administered as desensitizing or flare protocols on hormonal function in the luteal phase of hyperstimulated cycles.
    Norman RJ; Warnes GM; Wang X; Kirby CA; Matthews CD
    Hum Reprod; 1991 Feb; 6(2):206-13. PubMed ID: 1905309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of gonadotropin-releasing hormone (GnRH) Agonists Triptorelin Acetate and Cetrorelix Acetate in Assisted Reproduction.
    Jiang J; Gao S; Xu J
    Med Sci Monit; 2018 Nov; 24():7996-8000. PubMed ID: 30405094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
    Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
    J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation.
    Frydman R; Cornel C; de Ziegler D; Taieb J; Spitz IM; Bouchard P
    Fertil Steril; 1991 Nov; 56(5):923-7. PubMed ID: 1936328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction.
    Araujo E; Bernardini L; Frederick JL; Asch RH; Balmaceda JP
    J Assist Reprod Genet; 1994 Feb; 11(2):74-8. PubMed ID: 7819706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.